EXTON, Pa.--(BUSINESS WIRE)-- Most surveyed rheumatologists, nephrologists and primary care physicians cite increased use of Uloric in the last six months. In addition, half of rheumatologists and 26 percent of nephrologists surveyed cite increased use of Savient’s Krystexxa in the same time period, based on the recent TreatmentTrends®: Gout report published by BioTrends Research Group. Uloric outperforms other uric acid lowering (UAL) therapies on most attributes including efficacy and short-term safety/tolerability while newcomer Krystexxa holds only a single competitive advantage over Uloric.
Surveyed rheumatologists, nephrologists and primary care physicians are more highly satisfied with Uloric compared to other UAL therapies. Krystexxa, after a few months on the market, is rated highly satisfied by 55 percent of surveyed rheumatologists and 40 percent of surveyed nephrologists. However, uptake of Krystexxa is hampered by a lack of familiarity across all three surveyed physician groups, but particularly among nephrologists and PCPs. In another BioTrends publication, LaunchTrends®: Krystexxa, rheumatologists report several additional hurdles with Krystexxa including its safety profile, particularly as relates to concerns regarding anaphylaxis and infusion reactions, its route of administration, and a narrow eligible patient population. Among those that are currently prescribing the drug, however, the results have been favorable.
Despite moderate to severe renal impairment being a contraindication for allopurinol, it is still prescribed for the majority of patients with renal impairment, regardless of severity. The one exception is rheumatologists who prescribe slightly more Uloric for their patients with severe renal impairment.
There are several therapies for gout in development including Ardea Bioscience’s RDEA594, BioCryst Pharmaceutical’s BCX4208 and Regeneron’s Arcalyst. Rheumatologists indicate their greatest familiarity with Arcalyst, with similar interest across all three products in development. RDEA594 was ranked “most valuable” by at least half of surveyed physicians. There is still an opportunity for new gout therapies that can achieve the therapeutic target of 6.0 mg/dL serum uric acid level in patients. Although surveyed rheumatologists, nephrologists and PCPs agree that this is an important therapeutic target, the majority of their moderate and severe patients have a SUA level of ≥6.0 mg/dL.
TreatmentTrends® Gout is a report that covers the use of UAL therapies as well as gout flare remedies for the treatment and management of gout among 101 rheumatologists, 55 nephrologists and 66 primary care physicians. The report focuses on current and future use of agents, patient market share, perceived strengths and weaknesses of the key UAL products, barriers to broader usage, promotional efforts and therapies in development. TreatmentTrends® are a syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products.
About BioTrends Research Group, LLC
BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical Other Health Medical Supplies Nursing General Health Managed Care